An electronic blood sugar monitor makes it easier for people with diabetes to manage their disease.

As WHO unveils S.A.R.A.H. (Smart AI Resource Assistant for Health), its new digital health promoter prototype powered by generative artificial intelligence (AI), and available in eight languages 24 hours a day, WHO’s Regional Director for Europe writes about harnessing innovation in health to help meet critical public health challenges, both now and in the future.  

Innovation has always been a driving force behind advancements in health, revolutionizing the way we prevent, diagnose, and treat diseases. And as we navigate through a rapidly evolving health landscape, embracing health innovation has become more crucial than ever. 

From cutting-edge technologies like mRNA vaccines to AI-driven diagnostics, the potential of innovation to transform healthcare is limitless. But for too long health has often been viewed as a passive beneficiary of innovation rather than a driver of it. 

It’s time to change this mentality and harness the power of innovation. The challenges we face, from global pandemics to rising chronic diseases, from a rapidly ageing population to the effects of climate change, demand creative solutions that prioritize the well-being of populations worldwide. 

Shifting mindsets to move health innovation needle

Our sector – health – can and should be at the cutting edge of new and innovative solutions, driven by technology including AI, which is going to fundamentally change every aspect of human life over the coming century. 

In fact, the IMF predicts that 40% of jobs will be affected by AI in some shape or form over the coming years, including in health and care. Further, AI products and services are expected to contribute $15.7 trillion to the global economy by 2030, more than the current output of China and India combined.

However, while technological advancements have made significant strides in healthcare, social innovations and policies also play a crucial role in addressing the complex needs of diverse communities. Innovation in public health goes beyond technological breakthroughs; it involves harnessing creativity, collaboration, and sustainability, to promote equitable access to quality healthcare.

To foster an environment conducive to innovation in public health, leaders and decision-makers must focus on responding to the needs of communities while closing the equity gap. 

We must shift the focus from solely economic returns to the broader public health impact of innovative solutions. By aligning policies with the goal of improving health outcomes for all, we can better address inequalities in healthcare access and deliver sustainable solutions that benefit society as a whole. 

Another strategic shift requires patients themselves to be co-creators and designers of innovation because patients are experts in their own right. They know how to navigate life living with cancer or diabetes or a physical/mental disability. Involving them in the full pathway of disease management will make solutions more relevant and sustainable, and encourage innovation at scale.  

Ecosystem approach 

As public health professionals, we are not always good at articulating how innovation meets health and societal needs. That’s why we need an ecosystem approach to innovation. By fostering collaborations between healthcare providers, technology companies, research institutions, and policymakers, a holistic ecosystem can be created to drive innovation in health.

In Ireland, for example, the Health Ministry joined forces with the Department for Business, Enterprise, and Innovation to set up the Health Innovation Hub, an incubator for public health solutions. Health workers in the Health Innovation Hub spend half their time delivering care and the other half working with start-ups and health tech companies: a clear example of an ecosystem approach.   

Digital solutions to health, such as telemedicine, are already a reality in some countries.

As we embrace innovation to tackle pressing global challenges, sustainability must remain at the core of our efforts. Innovations should not only address current needs but also contribute to long-term social, economic, and environmental sustainability. 

This requires a shift towards sustainable practices, circular economy models, and responsible innovation that minimizes negative impacts on both people and planet. 

Too often people tell me that striving for health equity is at odds with our market-driven societies; that equity somehow stifles innovation. I would strongly dispute that – there is no contradiction. But unfortunately, modern economics tends to focus only on improving efficiency – for example, getting more cancer screenings for the dollar, or squeezing the last ounce of productivity out of the health system.

 Equity – leaving no one behind – is not seen as the responsibility of the commercial sector but that of the state or the non-profit sector. This mindset also needs to change. 

A Wellbeing Economy values equity and not only revenue or “productivity”. It strives to make the world a safe and just place for humanity – and this is the true challenge for innovators.

The future is already here 

Innovation for health brings together experts from diverse fields such as medicine, engineering, data science, and behavioural psychology. But as health is about where people live, love, work, and play, it’s also about transportation, urban planning, and agriculture.

This interdisciplinary approach not only catalyses breakthrough discoveries but also nurtures a culture of cross-pollination, where ideas flourish, and boundaries are transcended – precisely the kind of culture that innovation needs to thrive. 

However, the pursuit of innovation for health is not without its hurdles. From regulatory barriers to financial constraints, from ethical dilemmas to data privacy concerns, the path to innovation is fraught with challenges that require careful navigation. Nevertheless, these challenges should not deter us but rather galvanize our resolve to push the boundaries of what is possible. 

By fostering a culture of innovation, nurturing creative minds, and empowering diverse stakeholders to collaborate, we can address the most pressing challenges of our time.

Embracing emerging technologies, exploring new frontiers in science and medicine, and prioritizing social innovations will pave the way for a more equitable, resilient, and sustainable future and help countries in the hard-pressed challenge of reaching the Sustainable Development Goals by 2030.

We are well and truly in an era of ever accelerating innovation in health, bringing with it boundless possibilities for improving our collective health and wellbeing, generating jobs, and growing our economies. But health leaders are not yet fully equipped to navigate this new world, so full of exciting potential, with confidence. 

The health sector must be ready and equipped to embrace innovation across all dimensions, strengthening health and wellbeing. Or run the risk of being left behind, squandering the opportunities of today and jeopardizing the very future of health itself.  The choice is clear.

Dr Hans Henri P. Kluge is WHO Regional Director for Europe

Innovation ecosystem for public health 

Digital health – WHO/Europe

AI ethics and governance guidance

Image Credits: Uka Borrgeaard/ WHO, Juliana Tan/ WHO, WHO.

Uganda’s Deputy Chief Justice Richard Buteera (centre) delivers the Constitutional Court ruling.

Uganda’s Constitutional Court ruled on Wednesday that the country’s draconian  Anti-Homosexuality Act 2023 complies with the country’s Constitution in all but four aspects. 

“We decline to nullify the Anti-Homosexuality Act 2023 in its entirety neither would we grant a permanent injunction against its enforcement,” Deputy Chief Justice Richard Buteera,  told the Kampala courtroom and a capacity Zoom audience of 500.

The four sections that were struck down by the five-judge panel – 3 (2c), 9, 11 (2d) and 14 – were “inconsistent with right to health, privacy and freedom of religion”, according to the court.

“The nullified sections had criminalised the letting of premises for use for homosexual purposes, the failure by anyone to report acts of homosexuality to the police for appropriate action, and the engagement in acts of homosexuality by anyone which results into the other persons contracting a terminal illness,” according to a statement from the court.

Buteera said that the mandatory reporting to authorities of people suspected of having committed homosexual offences violated individual rights.

While the court has struck down the possibility of landlords being imprisoned for renting premises to homosexuals, it has maintained that prison terms of up to 20 years for journalists “promoting homosexuality” were legitimate.

In delivering the unanimous judgement, Buteera said that constraints on the media aligned with sections of the country’s Communications Act and Anti-Pornography Act, which “aim to uphold societal morals by limiting the use of media to publish or broadcast offensive material”.

The Act’s legitimacy was contested by 22 Ugandan human rights advocates including Member of Parliament Fox Oywelowo Odoi (the only MP to vote against the Act), legal academics Prof. Sylvia Tamale and Rutaro Robert and Bishop James Lubega Banda.

They said that it violated various constitutional rights, including the right to privacy and freedom from discrimination, as well as going against Uganda’s international human rights  commitments.

Frank Mugisha, of Sexual Minorities Uganda and Convening for Equality co-convener, described the ruling as “wrong and  deplorable”, and called on “all governments, UN partners, and multilateral institutions such as the World Bank and the Global Fund to likewise intensify their demand that this law be struck down”.
“This ruling should result in further restrictions to funding for Uganda – no donor should be funding anti-LGBTQ+ hate and human rights violations,” said Mugisha, one of Uganda’s most prominent LGBTQ activists.

Nicholas Opiyo of human rights group Chapter Four Uganda, said his organisation “vehemently disagrees” with the court’s finding and the basis on which it was reached.

“We approached the court expecting it to apply the law in defence of human rights and not rely on public sentiments, and vague cultural values arguments,” said Opiyo.

Life sentence and death penalty

Transgender rights
Protests have been held worldwide in support of the Ugandan LGBTI community as it faces attack.

The Anti-Homosexuality Act introduces “the offence of homosexuality”, with a potential life sentence for a same-sex “sexual act”. It also allows the death penalty for “aggravated homosexuality”, including sex acts with children, disabled people or those drugged against their will, or committed by people living with HIV – actions that are already criminalised by other laws.

Since the Act was passed last May, the World Bank has suspended new loans to Uganda and the US President’s Emergency Plan to Fight AIDS (Pepfar) has declined to advance plans for the country. There has also been widespread condemnation of the law.

Buteera claimed that the Act had been passed “against the backdrop of the recruitment of children into the practice of homosexuality. That is the mischief that Section 11 [dealing with the “promotion of homosexuality”] of the Act seeks to address.”

‘Absence of global consensus’ on LGBTQ rights

The court presented seven points as the basis for its decision, including that “sister jurisdictions” have “decriminalised consensual homosexuality between adults in private space”.

However, it referred to the absence of global consensus “regarding non-discrimination based sexual orientation, gender identity, gender expression and sex characteristics (SOGIESC)”. 

“This is reflected in the fact that to date non-discrimination on the basis of the SOGIESC variables has not explicitly found its way into international human rights treaties. Instead, it has been ‘vetoed’ by a bloc of resistant (UN) member states that has prevented the adoption of a binding declaration or similar instrument to strengthen protections for LGBTI human rights,” according to the court.

The court also referred to conflicts between “a universal understanding of human rights and respecting the diversity and freedom of human cultures” and between “individuals’ right to self-determination, self-perception and bodily autonomy, on the one hand; and the communal or societal right to social, political and cultural self-determination” on the other.

Finally, it described the Anti-Homosexuality Act as “a reflection of the socio-cultural realities of the Ugandan society, and was passed by an overwhelming majority of the democratically elected representatives of the Ugandan citizens”. 

Win for government

Dr Adrian Jjuukho, Ugandan human rights lawyer and executive director of Human Rights Awareness and Promotion Forum (HRAPF), which was one of the petitioners against the Act, described the ruling as “only intended to please donors in the health sector so that they can continue to provide the funds that are much needed while sacrificing LGBTI persons in the process”.

“The Court has nullified provisions that directly impede health service provision including reporting obligations, and where the victim acquires a terminal illness. This clears the way for health funding but does not actually clear the way for proper service provision,” said Jjuukho, writing on X (Twitter).

In a guarded statement, UNAIDS Regional Director for Eastern and Southern Africa Anne Githuku-Shongwe, said that “evidence shows that criminalizing populations most at risk of HIV, such as the LGBTQ+ communities, obstructs access to life-saving health and HIV services, which undermines public health and the overall HIV response in the country.”

“To achieve the goal of ending the AIDS pandemic by 2030, it is vital to ensure that everyone has equal access to health services without fear,” she added. UNAIDS provided evidence in support of the petitioners on certain clauses via an amicus brief.

Meanwhile, Ugandan feminist lawyer Sunshine Fionah Komusana told Health Policy Watch that “the ruling impacts everyone”.

“With the kind of government we have, I don’t know how anyone would be celebrating, knowing very well the different tags they use to deny people freedom of expression and association.,” said Komusana.

“Anti-human rights groups are gaining ground and before we know it, these kinds of legislation will be feeding into retraction of several other rights. See examples of reintroduction of legislation to legalise female genital mutilation and child marriages in some countries. These legislations harm all of us.”

Hundreds of people have already been arrested and attacked since the Act was introduced last May. In one case, a man was attacked in his home by a group of men one night. He was beaten and some of his property burnt by the mob, which accused him of being a homosexual.

In a similar incident, a lesbian was attacked by two men in her home. She had been evicted by her landlord on the grounds of homosexuality but did not have the resources to move.

International reaction to the court’s ruling will no doubt be keenly watched by countries contemplating their own anti-LGBTQ laws, such as Ghana, Kenya, South Sudan and Tanzania.

In February, ​​Ghana’s Parliament unanimously passed one of the world’s most draconian anti-LGBTIQ Bills which includes a mandatory three-year prison sentence for a person who simply “identifies” as lesbian, gay, bisexual, transgender, intersex or queer”. However, the president has yet to sign it into law.

Image Credits: Alisdare Hickson/Flickr.

Although smallpox has been eradicated, it is possib;le to recreate it from published genomes.

In the wake of surging mpox cases in the DRC and the emergence of novel orthopoxviruses, the US needs to rapidly bolster its smallpox readiness, preparedness, and response, according to a new report from the National Academies of Sciences, Engineering, and Medicine. 

The report brought together experts from across the country to critically evaluate the state of smallpox vaccines, diagnostics, and therapeutics, known as medical countermeasures (MCMs), in the event of an outbreak.

Improving MCMs is crucial for enhancing the nation’s ability to combat a smallpox outbreak or deliberate attack, the report emphasizes. It also stresses the importance of fortifying public health and healthcare systems to swiftly and effectively respond, including mechanisms for rapid vaccine distribution.

An ‘evolving bio-threat and technology landscape’

With advancements in genome sequencing and editing technology, it is now possible to recreate live smallpox virus from published genomes, the report warns. 

US population changes and advancements in gene editing and synthesis technologies have drastically altered the potential for a smallpox outbreak or attack in recent years. But these technologies significantly raise the risk of accidental or intentional release, challenging readiness planning and potentially altering the epidemiology and clinical presentations of the disease. 

The report notes that even if all existing collections of the virus were destroyed, reemergence is still a threat.

Despite the risks, the report underscores the necessity of continued research involving live variola virus for developing and enhancing smallpox MCMs. This research is essential for creating more effective therapies, validating vaccine and treatment efficacy, and establishing animal models for research purposes.

Research using these viruses can also fill gaps in our fundamental understanding of orthopoxvirus biology, ecology, evolution, transmission, and disease onset in humans.

A call for MCM research and development

Three main categories of MCMs need improvement: diagnostics, vaccines, and therapeutics. More accurate diagnostic tests to detect smallpox and related viruses at earlier stages is paramount. 

Vaccine safety is also an issue, and the report calls for research into vaccines that can be used across different populations and that are available as a single dose. 

“Developing new smallpox vaccines that use a multi-vaccine platform – which use common vaccine vectors, manufacturing ingredients, and processes – would improve the capacity for rapid production and reduce the need for stockpiling.”

Lastly, the report advocates for safer and more diversified therapeutics, such as antivirals with different and diverse targets, mechanisms, and routes of administration, to supplement existing antivirals. 

Vulnerabilities: too few manufacturers

The smallpox vaccine protects against mpox. 

The report concluded that the small number of manufacturers capable of producing smallpox medical countermeasures is a specific vulnerability, and that there is currently insufficient capacity to scale production in the event of a large outbreak or attack. 

Logistics and supply chain management planning is critical, as is planning for regulatory responsiveness. Clinical and public health guidance also needs to be updated to reflect new data and medical countermeasures so that health care providers and others on the front line of public health have the capability and capacity to respond to smallpox.

The need for global cooperation

Both the COVID-19 pandemic and mpox outbreaks revealed gaps in the US’s ability to respond to new infectious diseases. Specifically, the COVID-19 pandemic exposed weaknesses in the ability of US public health and health care systems to adapt and respond to an unfamiliar pathogen. Mpox, on the other hand, showed the challenges of rapidly making diagnostics, vaccines, and therapeutics available at scale.

Furthermore, the mpox outbreak brought to light the lack of diverse smallpox therapeutics options. Currently, standard research methods rely on challenge studies in animals to understand MCM efficacy in humans, leading to issues with accurately understanding the safety and efficacy in humans. 

“The gaps in our ability to respond to a new infectious disease were revealed by the COVID-19 pandemic and recent mpox outbreak,” said committee chair Prof Larry Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown Law and professor of medicine at Georgetown University.

“It is vital to prioritize research into the development of safer and more effective smallpox diagnostics, vaccines, and therapeutics, make judicious choices in stockpiling, and have modern, well-practiced, and adaptable plans for responding in the event of a smallpox outbreak,” added Gostin, who is also director of the WHO Collaborating Center on National and Global Health Law.

Research and development for these MCMs needs to not only consider the actual device or product, but also the ability to “deploy at scale” and equitably to meet the challenges of public acceptance.

The report urges effective risk communication for vaccines, as the same challenges with vaccine hesitancy and misinformation could occur in a smallpox outbreak.

While the report primarily focused on US readiness and response capabilities, it does note the impact of growing global interdependence in detecting and containing potential smallpox outbreaks.

“The COVID-19 pandemic and pox multi-country outbreak, both declared Public Health Emergencies of International Concern (PHEIC) by WHO, underscore the need for further domestic global coordination for preparedness and response against novel pathogens including orthopoxvirus events,” note the report authors. 

This means preemptively supporting international MCM capacity as any US response will be “significantly affected” by the ability of other countries to detect and surveil. The report notes that global solidarity is a key component to rapidly identify, contain, respond, and ensure equitable MCM allocation in a smallpox event.

Preparedness for similar viruses

Smallpox-related viruses such as mpox, Alaskapox, and cowpox are increasingly found in humans, magnifying the need for medical countermeasures that can detect, treat, and prevent these diseases.

The report notes that most mpox therapeutics were developed because of investments in smallpox therapeutics. 

“Direct investment in developing therapeutics targeting circulating orthopoxviruses could similarly benefit smallpox therapeutic preparedness and would likely have more immediate utility and potentially achieve commercial viability.”

Image Credits: Isao Arita/ WHO.

monkeypox
A patient participating in a clinical trial of Tpoxx, an antiviral treatment for the mpox virus, in the Central African Republic.

At a time when the world is negotiating the best way forward for sustained preparedness to address pandemics, it is still exhibiting collective failure to learn from past outbreaks and a glaring gap in global health security. Mpox is one case in point – and a test case for global intent on pandemic preparedness. 

In a remote village in Niger Delta Region of Nigeria, a 55-year-old man’s life was forever changed by mpox. For weeks, he suffered alone, his body and face ravaged by extensive lesions. 

Shunned by local health clinics and stigmatized by his community, he endured not just the physical agony of mpox but also its profound psychological toll. By the time he reached a hospital willing to treat him, it was too late to save his vision, permanently impaired by keratitis.

In the Democratic Republic of the Congo (DRC), a mother in the Mongala province faced the agony of watching her three children suffer from mpox. The eldest child, aged seven, was the first to contract the disease. As all the children shared clothes, the younger siblings, aged four and five, fell ill too, weaving a tapestry of shared suffering.

Human cost of inaction 

These heart-wrenching stories are a stark reminder of the human cost of inaction. Far from being isolated incidents, they painfully illustrate the dire consequences of global neglect in addressing mpox, particularly in Africa. 

For over 50 years, this African disease has been neglected by the international community with limited or no investments in surveillance.

Despite the growing threat posed by the disease, almost no mpox vaccines and few therapeutics have reached Nigeria, DRC or other West African countries at the epicenter of the epidemic. 

Moreover, critical funding for research and the development of more effective, affordable and accessible diagnostic tools, vaccines, and treatments remains woefully insufficient.

Caused by the monkeypox virus (MPXV), mpox has been endemic in most parts of central and western Africa since the 1970s, after first being discovered in 1958 when two outbreaks of a pox-like disease occurred in colonies of monkeys kept for research.

Until very recently, the more pathogenic clade I strain of the MPXV was restricted to a few Central African countries, particularly the DRC. Infants, children and young adults, mostly in rural settings and in close contact with the animal reservoir, experienced stigma, and excruciating pain due to mpox skin lesions and frequently severe disease that led to deaths. 

The clade II strain, which is common in West Africa, causes less severe disease but also negatively impacts on the health and socioeconomic livelihoods of affected patients and their families.

In Africa, the disease was largely spread from animal-human spillover events, with only a few, limited cases of human-to-human transmission within households, before transmission would ‘burn out’ locally. 

Unfortunately, due to poverty, weak health systems and other resource-constraints, countries, communities and families facing the challenge of mpox were unable to adequately respond and contain the disease. But the virus continued to evolve and mutate so as to be more effective in transmission to humans, including sexual transmission.  

More dangerous Clade 1 infections spreading rapidly 

Men queuing for the mpox vaccine in Chicago in the US. Many African countries have yet to receive mpox vaccines despite the disease being endemic in parts of central and west Africa.

In July 2022, the World Health Organization (WHO) declared mpox a public health emergency of international concern (PHEIC) on account of the global spread of the disease to over 100 countries in all continents of the world. For the first time in history, many countries outside Africa were reporting community transmission of mpox without any travel link to previously endemic African countries. 

Whereas prior outbreaks of mpox in Africa were largely zoonotic related, in 2022, mpox was unusually spreading mostly among gay, bisexual and men who have sex with men (GBMSM) by sexual contact.

The declaration of mpox as a PHEIC was intended to foster immediate and coordinated international action to contain the virus and prevent its further spread. The WHO external situation report of the 2022 multi-country outbreak has continually emphasized the significant knowledge gaps regarding route of transmission and risk factors for mpox among affected African countries. 

Although mpox now seems to have been contained in most high-income countries, little has changed in West and Central Africa where the disease is endemic. The story of neglect remains largely the same.

The DRC, meanwhile, remains in the throes of its largest outbreak ever. Since January 2023, over 12,000 suspected cases have  been reported in the DRC, only 9% of which were definitively laboratory tested due to resource-constraints. 

In November 2023, the WHO announced the detection of clusters of mpox cases linked to sexual contact among GBMSM in the DRC, the first reports of sexual transmission of the clade I strain in history. 

This unprecedented observation should be a wake-up call to re-examine investments and commitments to address the challenge of mpox in previously endemic countries, to avert another re-emergence of a global health emergency due to mpox.  

The first few months of 2024 reflect  an alarming surge in suspect cases and fatalities due to mpox, surpassing figures from the previous two years. 

WHO responses 

The WHO has developed a standing recommendation and a medium- to long-term mpox strategic response plan. To inform development and deployment of mpox-related medical countermeasures such as therapeutics and vaccines, the WHO published Target Product Profiles and developed a core protocol for the conduct of therapeutic clinical trials related to mpox. 

Affected countries, mostly high-income countries in Europe and America, have intensified risk communication and social mobilization, heightened surveillance and deployed existing smallpox-related vaccines and therapeutics (thought to be cross-protective against mpox) for use by the most at-risk social groups under an emergency use authorization.

These include MVA-BN, produced by the Belgium-based Bavarian Nordic and LC16 KMB, produced by Japanese firm KM Biologics. 

As clinical efficacy trials on mpox vaccines and therapeutics were lacking, many collaborative efforts were initiated or strengthened, to facilitate the conduct of mpox clinical trials. These coordinated international responses led to a sustained global decline in the number of new cases of mpox and the outbreak was effectively contained in most countries outside Africa by December 2022. In May 2023, the WHO declared an end to the mpox global emergency.

While declaring the end to the mpox emergency, the Mpox Emergency Committee indicated that “the gains in control of the multi-country outbreak of mpox have been achieved largely in the absence of outside funding support and that longer-term control and elimination are unlikely unless such support is provided”. 

‘Not one dollar’ to support mpox in endemic countries

And yet, as Dr Mike Ryan, Executive Director of the WHO Health Emergencies Programme, pointed out: “[mpox] is a neglected disease […]. In fact, WHO had to fund all of this international response purely on the basis of a contingency fund for emergencies. Not one dollar was received from donors to support this response and support countries.”

That means no donor funds have been available to strengthen mpox diagnosis, treatment, vaccination and control in the endemic countries like DRC, Nigeria and other neighboring countries in West Africa. Regardless of the risks posed to people in the region – or globally. 

Moreover, neither of the existing vaccines, both only available in limited supplies, are ideal for low- and middle income settings. The MVA-BN requires two jabs while the LC16 KMB is administered intradermally, a procedure unfamiliar to many rank-and-file health workers in low and middle-income countries (LMICs). There is a need to fund research for adapted, affordable and available medical countermeasures.

Today only tecovirimat, an oral treatment developed by SIGA, has received approval for use, based on animal data, in the European Union (EU) and US. 

When mpox cases rose, it was decided that a robust controlled clinical trial, confirming tecovirimat’s efficacy and safety in patients with mpox would be needed. 

Tecovirimat has to be administered twice daily after a solid food meal, and it is being investigated in the DRC in supervised, hospitalized patients. No data have yet been generated for any other African country where Clade II occurs, nor in an outpatient setting.  No other treatment has yet been investigated in patients. Tecovirimat is not approved in any African country and not yet available, even for compassionate use in Africa in clinical routine care.

Five clinical trials

Globally, there are currently only five randomized trials being conducted or planned on mpox treatments: UNITY (Switzerland, Brazil, Argentina), EPOXI (Europe), STOMP (USA, International), PALM007 (DRC) and MOSA (Benin, Cameroon, Central African Republic, Congo Republic, DRC, Ghana, Liberia and Nigeria). 

All the trials are testing tecovirimat as monotherapy. STOMP and PALM007 are funded through NIH/NIAID.  MOSA is a platform adaptive trial in Africa that could test other treatment arms, which is sponsored by PANdemic preparedness plaTform for Health and Emerging infectious Response (PANTHER) and receives partial support from the European Union.  

Horizon Europe is funding mainly the EPOXI trial in Europe, although it is also  providing some support to UNITY.

However, there is still a large funding gap to cover for the completion of those trials, especially in Africa. Furthermore, whereas various north south collaborations between African scientists and other researchers from across the globe are ongoing, there are still glaring gaps in investments in mpox surveillance, as well as available diagnostics and treatments in affected countries. 

In Africa, children worst affected 

While in the Clade II global health emergency, most of the victims were men, in Africa, the Clade I victims are now mostly children under the age of 16. 

The number of skin lesions that each person with Clade I experiences is much higher – up to several hundred in comparison with tens in Clade II. Bacterial infections and  underlying malnutrition can increase morbidity and the case fatality ratio is definitely higher in Africa than in high income countries. Those features are contextual and must be considered during drug development as they may significantly affect treatments’ strategies and overall efficacy.

At the same time, if mutations in Clade I mpox in the DRC are changing the pattern of infection and transmission, then new treatments are all the more critical to not only end the local outbreak but to prevent it from spreading more widely via sexual contact and other means.  

Test of humanity

The tardiness of action on mpox demands an immediate and concerted effort from the international community. By prioritizing research and vaccine development, enhancing international collaboration, and addressing stigmatization, we can strengthen our global preparedness for emerging health threats. As recently stated by Africa CDC, “vulnerable populations worldwide must have access to life-saving interventions”.

We stand at a crossroads between repeating past oversights and forging a new path of true equity and foresight. We cannot afford to repeat the mistakes we made over Ebola when funding was only made available when high-income countries were at risk.

It is time to harness the spirit of international collaboration. Building on positive initiatives like the UNITY trial, nations must come together to address the unique challenges posed by mpox and respond to the specific needs of  African patients.

Mpox isn’t just a test of our global intent on preparedness – it’s a test of our humanity. In honoring the memory of the young victims, like an eight-day-old baby girl in DRC, we must pledge to do better, act faster, and create a global health infrastructure that is as inclusive as it is effective.

Prof Jean-Jacques Muyembe Tamfum is the Director General of the DRC’s National Institute of Biomedical Research (INRB) in Kinshasa, Professor of Microbiology at the University of Kinshasa Medical and the inaugural president of the Congolese Academy of Science. He is co-discoverer of the Ebola virus in 1976 and co-inventor of the monoclonal antibody “ mAb114”, approved by FDA as an Ebola treatment, Ebanga, in December 2020. The INRB is conducting the PALM007 study on Tecovorimat in mpox patients.

Prof Dimie Ogoina is a Professor of Medicine and Infectious at the Niger Delta University Teaching Hospital in Nigeria. Ogoina’s team were the first to describe sexual transmission of mpox in Nigeria in 2017. He was a member of the World Health Organization IHR Emergency Committee on the multi-country outbreak of mpox.

Prof Francine Ntoumi is head of the Congolese Foundation for Medical Research, which she founded 15 years ago. She has over 20 years of experience in basic and clinical research in infectious diseases particularly malaria, HIV and tuberculosis, in endemic countries and Europe. 

Dr Nathalie Strub Wourgaft has been Delegate General for the PANdemic preparedness plaTform for Health and Emerging infectious Response (PANTHER) since its creation in 2022. Prior to that, she was Director of NTDs and later for COVID and pandemic preparedness at the Drugs for Neglected Diseases Initiative (DNDi) from 2009 to 2022. 

Prof Samba Sow is Director of CVD-Mali. A medical doctor and epidemiologist, Sow was Minister of Health and Public Hygiene for Mali between April 2017 and May 2019 and instituted a series of health sector reforms to provide free antenatal and maternal healthcare as well as free care for children under five years old. In 2020, he was appointed WHO Special Envoy for COVID-19 in West Africa.

Spring Gombe is the Strategic Policy Advisor to PANTHER, providing policy and program management support to entities working with vulnerable and marginalised groups with limited access to health technologies.

Jessica Ilunga is the Co-founder and Strategic Communication Partner of Galuni Consulting Associates, an Africa-focused advisory firm based in Brussels. She previously worked as Communications Director at the Ministry of Health in the DRC.

Image Credits: TRT World Now/Twitter .

Save Hands for Girls campaigns against female genital mutilation in The Gambia by working with schools, parents and organisations.

Global health and parliamentary leaders have offered to support The Gambia to maintain its  ban on female genital mutilation (FGM), expressing “profound concern” over a recent attempt to reverse the ban. 

The business committee of Gambia’s parliament is currently contemplating whether to allow the passage of a Private Members Bill which aims to reverse the landmark Women’s (Amendment) Act of 2015, which outlawed FGM.

The Bill was introduced by Almameh Gibba, an MP from the Alliance for the Patriotic Reorientation and Construction (APRC), with the support of Imam Abdoulie Fatty, a notorious proponent of FGM. The process involves the partial of total removal of external female genitalia – supposedly to “control” women’s sexuality – and is usually performed on girls under the age of 15.

But this attempt to reintroduce FGM has been condemned by the leadership of both the Partnership for Maternal, Newborn & Child Health (PMNCH), the world’s largest alliance for women’s, children’s, and adolescent’s health and well-being, which is hosted by World Health Organization (WHO), and the Inter-Parliamentary Union (IPU), the global organisation of national parliaments.

They urge the Members of the National Assembly to continue to protect the “hard-won” ban on FGM, warning in a statement issued over the weekend that repealing the ban “would not only undermine this progress but also perpetuate a cycle of discrimination and violence against women and girls”.

Despite the banning of FGM nine years ago, almost three-quarters of Gambian women are estimated to have been subjected to the practice, and almost half were cut before their 15th birthday.

There has only been one FGM-related conviction in the past nine years involving three women for cutting babies aged four to 12 months old, according to women’s rights activist Jama Jack. They received fines which were paid by Fatty via a public fundraising campaign, added Jack.

‘All possible support’

“We pledge all possible support to The Gambia in strengthening its efforts to prevent and address this harmful practice through multi-sectoral actions. This includes ensuring robust enforcement mechanisms, increasing access to quality healthcare services, and promoting gender equality and women’s empowerment initiatives,” according to the statement, which is signed by PMNCH leaders Helen Clark, Joy Phumaphi, Githinji Gitahi and Flavia Bustreo, and IPU Secretary General Martin Chungong.

“FGM is a grave violation of human rights and a harmful practice with severe health consequences, including physical, psychological, and reproductive and sexual health complications,” they add.

“FGM is associated with increased risks of postpartum hemorrhage, perinatal death, as well as urinary tract infections, menstrual difficulties and mental health conditions over the life course of women and girls.”

The PMNCH and the IPU emphasise the importance of upholding international human rights standards and commitments to protect women and girls from all forms of violence and discrimination.

“As a signatory to various international instruments, including the Convention on the Rights of the Child (CRC), Convention on the Elimination of All Forms of Discrimination against Women (CEDAW), the African Charter on the Rights and Welfare of the Child (ACRWC) and the Protocol to the African Charter on Human and People’s Rights on the Rights of Women in Africa (Maputo Protocol), The Gambia has a duty to uphold its obligations to its people and prioritize the health and rights of its population,” they remind the country.

Domino effect?

“Combatting FGM requires partnership at all levels. Parliamentarians can develop and uphold comprehensive legal frameworks; opinion leaders, including faith leaders, are needed to speak out firmly against the practice; community members, including health workers, can carry out powerful awareness campaigns based on lived experience, ensuring that care and support for survivors are integrated into sexual, reproductive, maternal, newborn, child and adolescent health (SRMNCAH) services.”

Meanwhile, Bustreo, who chairs PMNCH’s governance and ethics committee, said that her organisation was concerned about potential copycat moves.

“The concern lies in the potential for a domino effect if an anti-FGM law is repealed, signaling to others that similar regressive steps are acceptable,” Bustreo told Health Policy Watch.

“This isn’t merely about changing legislation; it’s about preserving the progress made in safeguarding the rights and well-being of women and girls. Repealing such laws threatens to erase years of dedicated advocacy and community engagement.” 

Around 90% of women in Somalia, Guinea and Djibouti are subjected to FGM, and a range of organisations fear that The Gambia’s reversal will encourage other countries in West Africa to follow suit.

Over 230 million girls and women alive today have undergone female genital mutilation (FGM), according to a report from the UN children’s agency, UNICEF, released earlier this month. This is a 15% increase since eight years ago.

Image Credits: Safe Hands for Girls.

Zero-emission vehicles powered by renewable energy could most likely avoid 1.9 million premature deaths, going up as much 2.4 million by 2040.

The International Council on Clean Transportation (ICCT), famous for busting Volkswagen’s Dieselgate, has a new ambition: Taking immediate action to shift to zero-emissions vehicles, significantly cutting ozone (O3) nitrogen dioxide (NO2) and PM2.5 pollution, and avoiding millions of cases of early death and paediatric asthma. Business-as-usual vehicle scenarios will lead to an increase. 

Because they breathe faster than adults, children are particularly vulnerable to emissions from vehicles. Toddlers are worse off because their shorter height means they’re closer to exhaust pipes. A new report has attempted to measure this and model various scenarios of controlling pollution from vehicles that would best protect children from asthma, and older people from air pollution-related chronic illnesses and premature deaths. 

The report, Global Health Benefits of Policies to Reduce On-Road Vehicle Pollution Through 2040, is by 10 authors, mostly associated with the ICCT. The group is perhaps best known for exposing Volkswagen for fudging on the true level of emissions from its popular diesel vehicles – known as the Dieselgate scandal. That cost the German auto giant billions of dollars and shifting producers away from the most health-harmful vehicle fuel. Now, the ICCT has turned its attention to the world’s vehicle fleet – analysing what would it take to reduce cases of early deaths and paediatric asthma over the next two decades. 

The authors say that their study, published in March as a Lancet pre-print, is the first of its kind to provide a globally consistent evaluation of this issue. They examined the impact of vehicular pollution at a one-kilometre resolution across 186 countries and territories that cover 99% of the global population. Fifteen emissions scenarios were evaluated representing different policy combinations. 

At one end is what the study calls the BASE scenario, where emission controls and policies analysed are as of March 2023, the time of this analysis. At the other end is the ALLZG scenario, the most ambitious one where all the best current and future technologies (like Euro 7 emission standard), are adopted for all sales of new internal combustion engines (ICE) in the world’s countries and territories. The ALLZG scenario also includes expedited rollout of zero-emission vehicles (ZEV), with renewable energy sources powering most of that shift. It further assumes countries would phase out older ICE vehicles, which don’t meet the most recent standards.  

Act to avoid premature deaths, children’s asthma

Children breathe faster and also are closer to the ground – thus more exposed to tailpipe emissions – ICCT.

Its conclusion is that the most ambitious ALLZG scenario could avoid 1.9 million premature deaths – and as many as 2.4 million between 2023 and 2040. People over the age of 65 would gain the biggest benefit in terms of avoided premature deaths. But in terms of illness, children would also benefit in a big way, especially in developing countries and urban areas. About 1.4 million cases of paediatric asthma could be avoided, with the projection rising to 1.7 million children – as many as half of them toddlers under the age of five. 

Under the business-as-usual scenario i.e. if government policies as of March 2023 remain in place, then annual deaths from transport-related emissions would increase from 182,000 annually in 2020 to 210,000 in 2040. Chronic obstructive pulmonary disease (COPD) or chronic lung disease, is the leading cause of air-pollution related premature deaths with cardiovascular disease, hypertension and cancer as other leading causes. 

Global South has the most to gain

Ozone concentrations are highest in African and Asian parts of the global south.

The study is preliminary and not peer-reviewed, the publishers point out. However, its data is broadly in line with trends and reality already observed especially about vehicular pollution.

Much of the Global South is way behind in controls. Many countries haven’t even implemented Euro 6, a diesel emission standard for vehicles first introduced in 2014 in the European Union, and a reference point for major manufacturers globally. It is also a truism that urban areas are more affected given the concentration of vehicles. Two-thirds of over 1.8 million new cases of paediatric asthma globally in 2019 occurred in urban areas. 

The report says that regions and trade blocs that mainly consist of countries in the Global South – Middle East, ASEAN (Southeast Asia), SAARC (South Asia), and ECOWAS (Africa) – have the greatest potential for mitigating new paediatric asthma cases from road transport emissions. Disparities in road transport-attributable health burdens are projected to widen amongst countries with different levels of development, with populations in countries with lower social demographic indices (SDIs) experiencing the largest increases in road transport-attributable health burdens. 

In countries without Euro 6 equivalent standards, implementing these could achieve 64% and 71% of the total benefits of all emission control measures combined for avoidable premature deaths and new paediatric asthma cases respectively. 

Most of the savings in lives from ozone (O3) would be in the global south, according to the analysis, published in preprint.

Overall, more than nine out of 10 fatalities are attributable to air pollution and the majority of the associated economic losses are concentrated in low-income and middle-income countries, and disproportionally affect children, the elderly, and socially vulnerable individuals.

One child’s death by vehicular pollution

Ella Roberta Adoo Kissi Debrah, who died on 15 February 2013 of a fatal asthma attack. She was the first air pollution victim to have that written as a cause on her death certificate, posthumously.

While the awareness about the links between air pollution and asthma has grown significantly, it has remained a more marginal issue in the air pollution debate, at least until the case of nine-year-old Ella Roberta Adoo Kissi Debrah who suffered from chronic asthma and died in 2013. Hers became the world’s first case where a death was officially attributed to air pollution. Initially, her death was merely attributed to acute respiratory failure. But  following a public campaign led by her mother, Rosamund Kissi-Debrah, a 2020 court ruling determined that her death should be attributed to levels of NO2 above the legal limits in her south-east London neighbourhood.

“The principal source of her exposure was traffic emissions.” The Coroner informed the court that “excess levels of nitrogen dioxide and particulate matter, PM10 and PM2.5, were a health risk, especially to children with asthma. Kissi-Debrah went on to found the Ella Roberta Foundation, campaigning against air pollution in the name of her late daughter. 

Still need an integrated approach 

Sadiq Khan, Mayor of London, has led a high-profile campaign to cut air pollution.

Bolstered by growing public awareness, London’s Mayor Sadiq Khan, who took office in 2016, has led a dramatic policy shift leading to sharp reductions in vehicular pollution. 

In March 2024, the mayor’s office announced that the roadside nitrogen dioxide (NO2) concentration levels had fallen by 49% between 2016 and 2023. NO2 levels were lower than even the first year of the COVID lockdown. The pandemic, moreover, vividly demonstrated to the public how a drastic reduction in traffic could reduce NO2, PM10, sulphur dioxide and carbon monoxide emissions, which are a direct or indirect result of burning fossil fuels for transport. 

As part of the shift, London has, of course, electrified vast chunks of its transport and tightened emission norms in lines with many of the recommendations of the new ICCT-led report.  However, the UK city also has created and expanded an ultra-low emission zone in the central city, greened public spaces, and created more cycling and pedestrian routes to encourage shifts to non-motorized transport along with improving public transport.

So while the London experience demonstrates that changes in vehicle emission policies can make a big difference, it also illustrates that an integrated approach remains critical – although the benefits of greener transport, mode shift, and greener urban planning remain to be quantified at a global level.

Not only that, but the climate impacts of reducing emissions also need to be considered along with the direct air quality benefits, as demonstrated in another report by ICCT, published late last year. That report focused on how reducing greenhouse gas emissions from vehicles could help limit global warming exceeding the 1.5° Celsius target climate scientists say needs to be reached to avoid greater catastrophic fallouts from extreme weather to the destruction of delicate coral reefs. Globally, road vehicles currently account for more than 20% of the carbon emissions from human activities, considering both fuel production and combustion. 

But both reports are clear.  To cut air pollutants from vehicles, policy action needs to be very ambitious and needs to start immediately, especially in the Global South. The Global North, as decades of climate negotiations have shown, needs to step up and transfer both green tech and money to the effort as fast as possible. Lives are at stake. 

Image Credits: Climateone.org , ICCT , ICCT , ICCT/The Lancet , Mayor of London .

CoViNet – The new network includes nearly 3 dozen research laboratories across the world with an expanded mandate.

The World Health Organization (WHO) has launched a new network, CoViNet, aimed at identifying, monitoring, and evaluating SARS-CoV-2, MERS-CoV, and emerging coronaviruses that pose significant public health risks.

The program expands on the WHO COVID-19 reference laboratory network, established in January 2020, in the early days of the pandemic.

Originally, the network’s primary goal was to offer confirmatory testing to countries lacking the capacity for testing SARS-CoV-2, including new variants. Over time, the requirements related to SARS-CoV-2 have changed. As such, CoViNet, with its “enhanced epidemiological and laboratory capacities,” according to WHO, will focus on tracking the virus’s evolution and the spread of variants and evaluating how these variants affect public health. The network brings together experts in animal health and environmental surveillance, other existing coronaviruses, and the identification of novel coronaviruses that could negatively affect human health. 

One Health focus 

The network will emphasize the significance of adopting a “OneHealth” strategy, the agency also added in a press release. The COVID-19 pandemic underscored the need for a comprehensive health approach that considers interactions among various species. The virus likely originated from a bat and was transmitted to humans through infected mammals kept and processed under unhygienic conditions at a market in Wuhan, China.

Finally, CoViNet will contribute to shaping WHO policies regarding public health and medical interventions. The data collected by CoViNet will inform the decisions of WHO’s Technical Advisory Groups on Viral Evolution and Vaccine Composition, among others. This will help ensure global health strategies and tools are grounded in the most up-to-date scientific insights.

“Coronaviruses have time and again demonstrated their epidemic and pandemic risk. We thank our partners from around the world who are working to better understand high-threat coronaviruses like SARS, MERS, and COVID-19 and to detect novel coronaviruses,” said Dr Maria Van Kerkhove, acting Director of WHO’s Department of Epidemic and Pandemic Preparedness and Prevention. “This new global network for coronaviruses will ensure timely detection, monitoring, and assessment of coronaviruses of public health importance.”

So far, 36 laboratories from 21 countries are involved in the network – from FIOCRUZ in Brazil to Geneva University Hospitals, Institut Pasteur in Dakar, Senegal, and Pakistan’s National Institute of Health.  Representatives from the labs met last week in Geneva to finalize an action plan for the next 12 months.

WHO has reported 6,932,591 coronavirus deaths and 766,440,796 cases since the pandemic began – although the real number of deaths worldwide is presumed to have been far higher. The pandemic was declared over last year, while the number of people dying from the disease has declined since the Omicron variant first detected in the fall of 2021 in southern Africa became dominant.  But WHO has continued to encourage countries to report weekly aggregate indicators of COVID-19 morbidity and mortality and variant surveillance data, warning that new variants of the virus, or other related emerging viruses could still pose a global health risk. 

Image Credits: WHO .

Al Shifa Hospital’s Surgery wing Monday April 1, 2024 after Israeli forces withdrew from the compound.

Israel said Monday that its forces had withdrawn from Shifa Hospital, Gaza’s largest health facility, after two weeks of fierce fighting with Hamas gunmen barricaded inside that destroyed large parts of the facility, including the surgery, maternity and emergency wards.  

WHO Director General Tedros Adhanom Ghebreyesus said Sunday evening that some 21 patients had died during the fighting. Around 107 patients trapped in the compound had been moved multiple times, lacking adequate food, medicines and access to clean water and sanitation for basic hygiene and wound care, he stressed.  

He added that a mission to Gaza, originally scheduled for Saturday, had to be postponed and urged Israel to “facilitate a safe humanitarian corridor and a better deconfliction system for WHO and partners to support patient transfers. 

Israel re-entered Shifa in a surprise attack early Monday morning, 18 March, saying that key Hamas leaders had regrouped inside following Israel’s first raid on the hospital in November. 

Israel said it had killed some 400 Hamas operatives in the two week operation, including the heads of the organization’s rocket unit and supplies, as well as senior intelligence figures. It detained 900 more people, of which it said 500 were found to be affiliated with Hamas or its ally, Palestinian Islamic Jihad. The army also released footage of weapons caches seized in the raids, reportedly from patient beds, drop ceilings and walls, saying other “valuable intelligence” had also been recovered.   

The Hamas-controlled Health Ministry in Gaza said some 400 people had been killed at Shifa hospital, including a female doctor and her son. Following Israel’s withdrawal, WAFA, the official Palestinian Authority news agency, said “hundreds of bodies of slain civilians” were strewn on the hospital grounds. The hospital’s few remaining patients were being moved to Al Ahli Hospital about two kilometres to the south-east, Reuters reported. 

Over 6,000 people had been sheltering on the hospital grounds when Israel first entered the compound, those who were not killed or detained fled in the first days of fighting. 

Al Aqsa Hospital compound hit by another attack  

Further south in Gaza’s middle region, WHO’s Tedros said that Al-Aqsa Hospital had been hit Sunday by an Israeli airstrike while a WHO team was on a needs assessment mission there, including the collection of incubators to be sent to northern Gaza. 

Tedros said that four people were killed in the attack, which hit a tent camp inside the hospital compound. But the WHO mission officers were unharmed.  Israel said that it had launched “a precision strike” at an “operational Islamic Jihad command centre” positioned in the hospital courtyard. It said that the hospital building was undamaged. The BBC said, meanwhile, that seven journalists including one BBC freelancer, were amongst those injured in the Israeli strike that hit a group of makeshift tents on the hospital grounds.   

Al-Aqsa Hospital is the only hospital located in the middle area of the Gaza Strip in Deir al-Balah and was founded in 2001. As of 2018, this hospital is one of 15 public hospitals in the Gaza Strip and is managed by the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA).

“We again call for protection of patients, health personnel and humanitarian missions. The ongoing attacks and militarisation of hospitals must stop. International humanitarian law must be respected,” Tedros said.

The fact that Israel decided to re-occupy Shifa reflects the success of Hamas regrouping in Gaza City, despite Israel’s ostensible control of the area since late last year, experts on the conflict have observed. 

Northern Gaza has been cut off militarily by Israel from southern Gaza for weeks during the fighting, complicating aid deliveries to the area from the southern part of the strip, including the border town of Rafah, while the grinding conflict continues over the month of Ramadan. Negotiations over an Israeli-Hamas ceasefire, including the release of some of the 100 Israeli hostages still held in Gaza, have progressed only in fits and starts.

UN agencies have sounded repeated warnings of increasing hunger and risks of famine, particularly in the north where food aid deliveries are perilous. Scenes of people being killed by food parcels parachuted from the sky or shot or run over by aid trucks further underline the chaos surrounding the logistics of aid delivery. 

The International Court of Justice last week ordered Israel to allow unimpeded access of food aid to Gaza, saying that “famine is setting in.” Israel has said that it will no longer cooperate with the UNRWA personnel in aid deliveries due to UNRWA’s alleged complicity in the Hamas 7 October attacks on Israel, complicating the logistics of food deliveries.  

Meanwhile, WHO and other international relief agencies face an uphill challenge in maintaining basic functionality, let alone rebuilding, Gaza’s damaged health system, while fierce fighting continues and the threat of an invasion of Rafah looms. Only nine out of 36 Gaza hospitals continue to function, and most of those are concentrated in the southern or middle part of the enclave.  They are complemented by several emergency field hospitals, set up and run by international donors, also in the south.   

INB co-chairs Roland Driece and Precious Matsoso.

The fractious pandemic agreement talks – supposed to end with an agreement on Thursday (28 March) – have limped into extra time, with World Health Organization (WHO) member states resolving to hold an additional intergovernmental negotiating body (INB) meeting from 29 April to 10 May.

The World Health Assembly (WHA), which begins on 27 May, is supposed to adopt the agreement, intended to be a global guide on how to prevent, prepare for, and respond to, pandemics.

But the best case scenario is for the WHA to adopt an “instrument of essentials”, a bare-bones text that will be fleshed out over the next 12 to 24 months in advance of the proposed Conference of Parties, according to people close to the talks.

At the briefing at the end of Thursday’s talks, which started almost four hours later than scheduled, INB co-chair Roland Driece said that “there is no champagne”.

“We had long intensive discussions, but we have not succeeded in concluding this meeting,” added Driece. 

Consensus text

Instead, the INB Bureau would get a revised text to member states by no later than 18 April.

However, this text would be different from the previous one as it would aim to draw out consensus points rather than provide a shopping list of issues.

“That text will be building on the current one but also be different in focus and in level of detail, like we discussed before, but still trying to operationalise equity as much as we can,” said Driece. “We will build on the consensus already identified. Consensus is an important word.”

Extract from the INB 9 reportback

The INB drafting group will focus on “agreeing text”, and member states were also urged to “provide the Bureau with any convergence text resulting from informal consultations, as soon as possible”.

Meanwhile, when the INB resumes, there will be space for “structured informal meetings or working groups, as needed, to progress the work”.

At the start of the two-week negotiations, a number of member states had complained that their proposals and agreements reached in sub-groups had not been reflected in the Bureau’s draft text.

The focus on consensus appeared to cheer delegates, including Switzerland which said there was “a clear way forward”. Switzerland had refused to accept the draft text at the start of the talks.

Meanwhile, WHO Director General Dr Tedros Adhanom Ghebreyesus implored delegates to draw on the “spirit of Geneva” to conclude the talks.

“Let the spirit of Geneva – the spirit of cooperation, mutual respect, and shared responsibility – guide your deliberations as you work towards finalising the agreement by the set deadline in May this year,” said a visibly tired Tedros.

“Together let us reaffirm our commitment to global health security, to solidarity in times of crisis and to a future where no one is left behind by operationalising equity with international law,” added Tedros.

WHO Director General Dr Tedros, flanked by WHO head of health emergencies, Dr Mike Ryan, at INB 9.

Putting on a brave face?

Finding consensus points may be hard in the coming days as many countries appear to have lost patience with one another, and with the INB Bureau and WHO Secretariat members who have been steering the process.

Countries across the political spectrum accused one another of refusing to make compromises, and criticised the Bureau for failing to provide direction.

However, the geopolitical reality is that some of the 194 member states are at war, while others are long-term trade enemies. This was never going to be easy, despite the recent trauma of COVID-19.

In the past two weeks, so much text has been added to the 31-page draft that the meeting started with that it had swollen to a completely unwieldy 100-page draft by Tuesday 26 March with multiple opposing clauses contained in brackets.

For example, by last Saturday (23 March), 50 countries had submitted at least one bracketed suggestion for Article 11, which deals with technology transfer, according to Knowledge Ecology International (KEI), which had two observers at the meeting.

However, the now notorious Article 12, which deals with pathogen access and benefit-sharing (PABS), remains the biggest obstacle.

The European Union believes that there is a place for intellectual property rights in PABS. However, this has been rejected by the Group on Equity – an alliance of 34 countries  – and the Africa region.

But the Group on Equity, which includes countries with large generic medicine producers such as India, Brazil and Indonesia, has also been accused of trying to secure advantages for these companies but taking a hard line on technology transfer.

Meanwhile, Colombia blamed the lack of progress in the past two weeks on “changing modalities, which were sometimes unclear, but also because we’re facing a highly complex document”.

“We support the Bureau in producing a streamline text and one which can achieve consensus but it will have to have substantive provisions which will take us beyond the status quo. The agreement that we will reach must be clearly based on the principles of equity and solidarity that tragic experiences that we live through during the COVID 19 pandemic.

Additional reporting by Elaine Ruth Fletcher

Farmworker Sonali Kadam has been finding it difficult to work in the fields during the summers because of unbearable pain caused by kidney stones.

Whenever farmworker Sonali Kadam experiences pain in her lower abdomen, she fears losing consciousness and pops a painkiller. 

Her fearful response goes back a decade when she was diagnosed with nephrolithiasis, commonly known as kidney stones, which are hard deposits of salt and minerals formed in the kidneys. 

When Kadam, a farmworker, first experienced this pain, she ignored it and kept working in the sugarcane fields. Within an hour, her pain aggravated, and she collapsed. 

Kadam, a resident of Arjunwad village in India’s Maharashtra state, has multiple stones in the kidney, each around 8mm in size. Usually, stones smaller than 5mm pass on their own through urine, while bigger stones might need medical intervention and sometimes even surgery.

In her quest to get rid of these stones, Kadam has consulted over 10 different doctors and took hundreds of painkillers but nothing worked. 

“This has traumatized me so much that whenever it starts paining, I fear I will either faint or die,” she told Health Policy Watch.

Kadam, 34, says her condition worsens in summers when the temperature tops 40° Celsius. As a farmworker, her day in the fields begins at 9am. There she sows seeds, clears weeds and harvests crops until about 5.30pm each day. 

“During this time, I am exposed to a lot of heat, which has been worsening my kidney stones,” she shares

Kidney disease rises with temperature

What Kadam has experienced isn’t a one-off case. Higher temperatures cause dehydration, leading to a rising concentration of minerals like calcium in the urine, which is responsible for the growth of kidney stones. 

A study published in the Lancet in March 2024 analyzed 135,4675 Acute Kidney Injury (AKI) cases in England between 2017 and 2021 and found a 62.3% increased odds of AKI when temperatures reached 32°C compared with that at 17°C. The researchers also found that in July 2021, a week-long heatwave led to a 28.6% increase in AKI counts. 

A study by the Children’s Hospital of Philadelphia in 2014 analyzed over 60,000 US patients and found a rising probability of people being diagnosed with kidney stones as daily temperatures rose. Researchers found that, at 30° C, the relative risk of kidney stone presentation was 36-39% higher than at 10° C.

Research from Australia points out that even a 1°C rise in daily minimum temperature increased emergency department admissions for kidney stones. 

Meanwhile, a paper in Nature’s Scientific Reports in January 2022 projecting the impact of rising heat on kidney stones in South Carolina, predicts that by 2089, even in the case of aggressive reduction in greenhouse gas emissions, the prevalence of kidney stones will increase by between 2.2% and 3.9%, costing an additional $57 million to $99 million respectively..  

According to the Global Burden of Disease study, 116 million cases of acute urolithiasis, a condition in which kidney stones move into the ureters, urethra, and bladder from the renal pelvis, occurred in 2019. 

This led to 13,300 deaths and 604,000 global disability-adjusted life years. For every 100,000 people, 1,394 were diagnosed with acute kidney stones. While there are no global projections yet, a rising chorus of experts are warning that kidney stones will rise sharply with the soaring temperatures.

“Global warming from climate change predisposes to kidney stones and acute kidney injury,” says Dr Matthew Borg, one of the authors and a biostatistician and research epidemiologist at t the University of Adelaide in Australia

Climate change can disrupt water treatment processes due to increased pollutant loads in heavy rainfall, which can decrease the availability of clean drinking water. 

“This can increase the risk of diarrhoeal diseases such as leptospirosis and schistosomiasis that, if not adequately managed, can cause dehydration and AKI,” Borg explains. 

There is already a 12% average prevalence of kidney stones worldwide, with 15% being the norm in Northern India. 

Unable to afford surgery 

Last year was the warmest year on the planet, during which India witnessed some of its deadliest heat waves. 

A report by international climate scientists found that human-induced climate change made the April 2023 heatwaves 30 times more likely in India and Bangladesh.  

Moreover, a paper published in PLOS Climate in 2023 found that heat waves can impact over 90% of India. 

Doctors have advised Vandana Badame to have surgery to remove her kidney stones, but she can’t afford it.

Three years ago, farmworker Vandana Badame felt a cramping pain in her side and back while working in the chilli fields in Maharashtra’s Ganeshwadi village. 

“The pain was unbearable. I kept puking and thought I was going to die,” 40-year-old Badame remembers. 

The culprit was a 9mm kidney stone. The doctors suggested surgery but she simply can’t afford it.

 Since then, she has relied solely on drinking water, hoping that the stone will pass through urine. But the kidney stone has caused her tremendous pain, which increases when she works in scorching heat. 

During such times, her only solution is to immediately go to a nearby clinic, take pain management injections, and continue working in the field. 

“Even if it pains, I have to keep working. What else can I do?” asks Badame, who is her family’s sole earner. 

Every month, she relies on intravenous drips to continue working in the fields. She gets 220 Indian Rupees ($2.65) for eight hours in the field, while an intravenous drip costs her at least Rs600 ($7). 

Whenever she steps out in the field, she carries five litres of water and painkillers. As the temperature increases, so does her vulnerability to the pain caused by kidney stones. 

A 2013 paper published in the International Journal of Environmental Health Research found that “the number of hot days in a year is positively correlated with the number of urolith patients”.

 Researchers also found that drought and semi-arid conditions in India made groundwater more saline, which is associated with the formation of kidney stones. 

Moreover, a 2020 study that analyzed 1500 industrial workers from South India exposed to extreme heat had a 2.3 times higher chance of severe health outcomes, with one third of steelworkers reporting kidney stones.

Lack of health facilities 

When farmworker Basappa Kamble, 51, collapsed from kidney stone pain at 1am in 2022, it took over an hour for him to reach the hospital. 

“There are no sonography facilities in the nearby areas,” says community healthcare worker Shubhangi Kamble, who rushed him to a private hospital where a 17 mm kidney stone was detected.  

“He was hospitalized for a week,” says Kamble. Despite the surgery, he complains of recurring pain. 

In his village, Arjunwad, with less than 6000 people, a majority are farmers, farm workers, and outdoor workers exposed to tremendous heat. 

Kamble started surveying her community and found that the problem of kidney stones peaked during summers. 

Workplace guidelines

“Workplace guidelines, such as enforced work to rest ratios, reducing physically strenuous work during the hottest hours of the day, and adequate access to good ventilation and shade, should be reviewed to improve workers’ safety in hot temperatures,” suggests Borge.

Besides this, he suggests general precautions like preparing for increased presentations of kidney stones and AKI, including staffing, equipment, training, and dialysis facilities during hot seasons.

However, for its 833 million strong rural population, India just has 764 district and 1224 sub-district hospitals catering to kidney ailments. 

“Since these hospitals are overcrowded and far away from villages, the only solution for many is to take a painkiller. Its overdose has led to several side effects,” shares Kamble. 

Farmworkers are forced to rely on costly private hospitals during such pressing times and a single doctor’s visit costs at least $6. Kadam and Badame earn this money after toiling in the fields for 16 hours. 

“Many times, I avoid going to the doctor and buy medicines from the pharmacy directly,” shares Kadam. 

Frustrated with the unbearable pain, sometimes she even ties a rope around her waist, attaches it to a firm object or a hook in the wall, and pushes herself against it. 

“This comforts me for a while. Every day, I feel like there is no end to this pain, and it will only go after I die.”

Image Credits: Sanket Jain.